Synthesis, crystal structure and cytotoxic activity of ruthenium(II) piano-stool complex with N,N-chelating ligand

Anticancer and antimicrobial properties of novel η6-p-cymene ruthenium(ii) complexes containing a N,S-type ligand, their structural and theoretical characterization

“…The exchange of neutral ligands for anionic ones does not change the "stiff" piano-stool geometry typical for the Ru(II)arene complexes e.g. ; [26][27][28][29][30] the angles around Ru atom remain alike in all the studied compounds ( Table 3). The overlays of the structures are presented in ESI as Fig.…”

Ruthenium(II) and Iridium(III) Complexes as Tested Materials for New Anticancer Agents

“…Moreover, in the presence of water, the ketone carbonyl group can undergo nucleophilic substitution, forming a gem-diol (see Scheme 1 e). The main goal of the present work was: (i) synthesis and full physicochemical characterization of the half-sandwich complexes: 4d 6 low-spin arene ruthenium(II) (1) and (5d 6 ) isostructural pentamethylcyclopentadienyl (Cp) iridium(III) (2) as well as tetrachloroiridate(III) (3) with Scheme 1. Selected coordination modes of the di-2-pyridylketone (py 2 CO).…”

“…The main goal of the present work was: (i) synthesis and full physicochemical characterization of the half-sandwich complexes: 4d 6 low-spin arene ruthenium(II) (1) and (5d 6 ) isostructural pentamethylcyclopentadienyl (Cp) iridium(III) (2) as well as tetrachloroiridate(III) (3) with di-2-pyridylketone (py 2 CO), (ii) determine the structure-activity relationships including not only classical coordination bonds but also noncovalent interactions in a crystal structure, and (iii) investigation of their types of interactions with selected biological targets (DNA, human serum albumin (HSA) and GSH). To achieve these goals, elemental analysis; single-crystal X-ray diffraction; 1 H, 13 C, and 15 N NMR; and FTIR, UV-Vis, PL and circular dichroism (CD) spectroscopy methods were successfully applied.…”

“…To achieve this, ruthenium and iridium complexes have been widely developed as alternatives to anticancer drugs based on platinum(II) complexes (for example: cisplatin [ 3 ], carboplatin, oxaliplatin [ 4 ], nedaplatin [ 5 ], etc.). We have previously reported [ 6 ] that, to overcome this problem, our investigation focused on the synthesis of the ruthenium(II) arene complex, [(η 6 - p -cymene)RuCl(2,2′-PyBIm)]PF 6 (2,2′-PyBIm = 2-(2′-pyridyl)benzimidazole). Such ruthenium complexes with a typical half-sandwich structure are well-suited as chemotherapeutic agents because the process of optimizing their activity against cancer cells involves easy modulation of their arene compounds and/or chelating ligands [ 7 ].…”

“…Such ruthenium complexes with a typical half-sandwich structure are well-suited as chemotherapeutic agents because the process of optimizing their activity against cancer cells involves easy modulation of their arene compounds and/or chelating ligands [ 7 ]. Unfortunately, while the obtained complex showed moderate activity against the tested carcinoma cells, it was also active against the normal BALB/3T3 cell line (IC 50 = 43.66 µM; but its cytotoxicity is 15 times lower compared with cisplatin) [ 6 ]. Taking this into account, during our following experiments, we tested whether a 2-(2′-pyridyl)benzimidazole replacement with 2,2-bis(4,5-dimethylimidazole) (L 1 ) in an arene ruthenium complex {[RuCl(L 1 )(η 6 - p -cymene)]PF 6 }·2H 2 O [ 8 ] could be a potential chemotherapeutic agent.…”